drugset / Trial / NCT00744081
Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to show superiority in complete responses of combination therapy MTC plus Glivec in patients with refractory or relapsed AML compared to a historical control which was treated with MTC alone.
Timeline
- Start
- 2004-07
- Primary completion
- 2010-12
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imatinib | Small molecule | — | — |
| Background | Cytarabine | Small molecule | — | — |
| Background | Mitoxantrone | Small molecule | — | — |
| Background | Topotecan | Small molecule | — | — |